Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) and Genmab A/S (NASDAQ:GMAB – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings.
Analyst Recommendations
This is a breakdown of recent recommendations for Dianthus Therapeutics and Genmab A/S, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dianthus Therapeutics | 1 | 0 | 13 | 2 | 3.00 |
| Genmab A/S | 0 | 1 | 10 | 1 | 3.00 |
Dianthus Therapeutics currently has a consensus price target of $128.77, suggesting a potential upside of 48.04%. Genmab A/S has a consensus price target of $53.50, suggesting a potential upside of 2.96%. Given Dianthus Therapeutics’ higher possible upside, equities research analysts clearly believe Dianthus Therapeutics is more favorable than Genmab A/S.
Volatility & Risk
Dianthus Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.
Valuation and Earnings
This table compares Dianthus Therapeutics and Genmab A/S”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dianthus Therapeutics | $2.04 million | 2,400.90 | -$162.34 million | ($3.99) | -21.80 |
| Genmab A/S | $3.72 billion | 8.72 | $963.00 million | $1.17 | 44.41 |
Genmab A/S has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Dianthus Therapeutics and Genmab A/S’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dianthus Therapeutics | -7,436.50% | -19.68% | -18.95% |
| Genmab A/S | 16.97% | 13.67% | 6.42% |
Insider & Institutional Ownership
47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.
About Genmab A/S
Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
